Our top pick for
Zymergen Inc is a chemicals business based in the US. Zymergen shares (ZY) are listed on the NASDAQ and all prices are listed in US Dollars. Zymergen employs 754 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$10.45|
|52-week range||$9.51 - $52.00|
|50-day moving average||$12.65|
|200-day moving average||$27.00|
|Wall St. target price||$17.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-11.17|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-5.00%|
|1 month (2021-09-24)||-22.01%|
|3 months (2021-07-26)||-69.75%|
|6 months (2021-04-26)||-75.70%|
|1 year (2020-10-22)||N/A|
|2 years (2019-10-22)||N/A|
|3 years (2018-10-22)||N/A|
|5 years (2016-10-22)||N/A|
|Revenue TTM||$18.7 million|
|Gross profit TTM||$-162,386,000|
|Return on assets TTM||-56.56%|
|Return on equity TTM||-197.7%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
There are currently 5.0 million Zymergen shares held short by investors – that's known as Zymergen's "short interest". This figure is 13.4% up from 4.4 million last month.
There are a few different ways that this level of interest in shorting Zymergen shares can be evaluated.
Zymergen's "short interest ratio" (SIR) is the quantity of Zymergen shares currently shorted divided by the average quantity of Zymergen shares traded daily (recently around 734340.76809453). Zymergen's SIR currently stands at 6.77. In other words for every 100,000 Zymergen shares traded daily on the market, roughly 6770 shares are currently held short.
To gain some more context, you can compare Zymergen's short interest ratio against those of similar companies.
However Zymergen's short interest can also be evaluated against the total number of Zymergen shares, or, against the total number of tradable Zymergen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zymergen's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Zymergen shares in existence, roughly 50 shares are currently held short) or 0.0854% of the tradable shares (for every 100,000 tradable Zymergen shares, roughly 85 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Zymergen.
Find out more about how you can short Zymergen stock.
We're not expecting Zymergen to pay a dividend over the next 12 months.
Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.